06 Oct 2025 Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025 Multiple categories
24 Sep 2025 Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer Multiple categories
23 Jul 2025 KU Leuven researchers identify promising drug for treating severe malaria Multiple categories
05 Jun 2025 AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology Multiple categories
07 May 2025 Remynd tests optimized septin modulator against Alzheimer’s disease in phase 1 clinical trial Multiple categories
28 Apr 2025 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Member news
10 Mar 2025 Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Member news
07 Jan 2025 Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology Member news
16 Dec 2022 Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
